The American Society of Clinical Oncology (ASCO) annual meeting, which ran from June 3-7 in Chicago, is closely watched by analysts and investors alike, and favorable data presented at the event can advance a company's stock valuation significantly. Equally, candidate cancer therapies that do not live up to expectations will see their developers face the ire of investors.